Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified - between 12 November 2014 and 10 September 2015

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the importation, supply, and advertising of therapeutic goods to ensure their safety, quality, and efficacy. In 2014, the Therapeutic Goods Administration (TGA) provided consent for the importation and supply of specific pharmaceutical products under Section 14 and 14A of the Act. This consent, granted to Alphapharm Pty Ltd, allowed for the temporary use of product labels that did not comply with the sponsor details requirement, reflecting a transitional phase following a change in sponsorship from Aspen Pharmacare to Alphapharm Pty Ltd. The consent was intended to facilitate the smooth transition and continuity of supply for these medicines, while ensuring that any concerns or complaints would be appropriately managed by the new sponsor.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, including medicines, medical devices, and blood and blood components, throughout the Commonwealth of Australia. The Act aims to protect public health by ensuring that therapeutic goods are of an acceptable quality, and by regulating their importation, supply, and advertising. The Act applies to both individuals and entities involved in the supply of therapeutic goods, including manufacturers, importers, and sponsors. It sets out various requirements and standards that these entities must meet, such as ensuring that products are safe, of acceptable quality, and properly labelled. The Act also provides for the regulation of clinical trials and research involving therapeutic goods. The Therapeutic Goods Administration (TGA) is the body responsible for administering the Act, and it has the power to issue approvals, certificates, and other authorisations necessary for the supply of therapeutic goods. The Act extends its reach through subordinate instruments, such as regulations and therapeutic goods orders, which provide more detailed specifications and requirements for particular types of goods or activities. While the Act is comprehensive, it does include certain exclusions and exemptions, such as for goods supplied for personal use or for use in research or teaching, and for certain types of medical devices that are subject to other regulatory frameworks. The Therapeutic Goods Act 1989 applies to both individuals and entities involved in the supply of therapeutic goods, including medicines, medical devices, and blood and blood components, across Australia. The Act sets out various requirements and standards for the quality, safety, and proper labelling of these goods, and regulates their importation, supply, and advertising. The Act applies to both domestic and international suppliers of therapeutic goods, and provides for the oversight and regulation of clinical trials and research involving these goods. The Therapeutic Goods Administration (TGA) is responsible for administering the Act, and has the power to issue approvals, certificates, and other authorisations necessary for the supply of therapeutic goods. The Act is supported by a range of subordinate instruments, such as regulations and therapeutic goods orders, which provide more detailed specifications and requirements for particular types of goods or activities. While the Act is comprehensive, it does exclude certain goods and activities from its scope, such as those supplied for personal use or for use in research or teaching, and for certain types of medical devices that are subject to other regulatory frameworks.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989, as applied by Alphapharm Pty Ltd, allow the delegate of the Secretary of the Department of Health to consent to the importation and supply of therapeutic goods that do not conform to certain regulatory requirements. In this instance, the consent permits the importation and supply of specific medicinal products, which have labels bearing the sponsor details of the previous sponsor, Aspen Pharmacare, instead of the current sponsor, Alphapharm Pty Ltd. This consent is valid from 12 November 2014 until 10 September 2015. The consent comes with conditions, one of which is that the labels in question are those previously approved for Aspen Pharmacare, and that there are arrangements for any queries or complaints concerning the products to be promptly referred to Alphapharm Pty Ltd. The Therapeutic Goods Act 1989 imposes specific obligations on parties involved in the importation and supply of therapeutic goods. For Alphapharm Pty Ltd, this includes ensuring that any queries or complaints about the listed products are managed effectively by referring them to the appropriate entity. Additionally, the Act requires Alphapharm Pty Ltd to comply with any other relevant conditions that the delegate may impose when granting consent under sections 14 and 14A. Breaching the conditions set forth by the delegate of the Secretary can lead to various legal consequences. While the specific Act does not detail maximum penalties for this type of consent breach, general provisions within the Therapeutic Goods Act 1989 suggest that significant penalties can apply for non-compliance with therapeutic goods regulations. These may include fines and potential criminal charges for serious or repeated breaches. The exact penalties would depend on the specific breach and the discretion of the courts. Furthermore, the Therapeutic Goods Administration retains the authority to take additional regulatory actions, such as product recalls or further restrictions on supply, to ensure public safety and compliance with health regulations.